🇺🇸 FDA
Pipeline program

NNC0487-0111 B 10143, NNC0487-0111 B 10144, NNC0487-0111 B 10145, NNC0487-0111 B 10142, NNC0487-0111 B 10146, Placebo, NNC0487-0111 B 10141

NN9490-8025

Phase 3 small_molecule active

Quick answer

NNC0487-0111 B 10143, NNC0487-0111 B 10144, NNC0487-0111 B 10145, NNC0487-0111 B 10142, NNC0487-0111 B 10146, Placebo, NNC0487-0111 B 10141 for Overweight or obesity, and obstructive sleep apnoea not treated with positive airway pressure is a Phase 3 program (small_molecule) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).

Program details

Company
Novo Nordisk A/S
Indication
Overweight or obesity, and obstructive sleep apnoea not treated with positive airway pressure
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials